Nakarai A et al. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count. World J Gastroenterol 2014; 20(48): 18367-18374 The degree of mucosal healing following a flare of ulcerative colitis (UC) may provide useful prognostic information. This retrospective cohort study of 169 UC patients with sustained clinical remission (≥6 months) investigated the prognosis of complete (Mayo endoscopic score (MES) 0, n=80) and partial (MES 1, n=89) colonic mucosal healing. Patients with MES 1 had a significantly higher risk of clinical relapse, hospitalisation and need for rescue corticosteroids compared to patients with MES 0 Gastroenterology 2014; 147:1296 -1307 Therapeutic infliximab monitoring may improve outcomes in the management of UC particularly in patients with poor response due to inadequate drug concentrations. This study analysed data from the active UC trials 1 and 2 (ACT-1 and ACT-2) post-hoc to assess the relationship between serum infliximab concentrations and clinical outcomes in 728 patients with moderately-to-severely active UC (MAYO score 6-12). Significantly greater median serum infliximab concentrations were associated with improved clinical response and mucosal healing at weeks 8, 30 and 54 and with clinical remission at weeks 30 and 54 regardless of the induction and maintenance doses (5 mg/Kg or 10 mg/Kg). For clinical response at week 8 a threshold infliximab concentration of 41 μg/mL was associated with a sensitivity, specificity and positive predictive value of 63%, 62% and 80% respectively. Furthermore to maintain clinical remission at week 30 a threshold infliximab concentration of 3.7 μg/mL was associated with a sensitivity, specificity and positive predictive value of 65%, 71% and 82% respectively. This study highlights the possible merits of targeted infliximab dosing according to serum drug concentrations. There is a need for prospective studies to further define the optimal serum infliximab concentrations to guide the management of patients with moderately-toseverely active UC.
Papers were prepared by:
Drs Luke Materacki and Ishfaq Ahmad, Alexandra Hospital, UK
